ABX-101 / Autobahn Therap - LARVOL DELTA

Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders (Businesswire) - "Autobahn Therapeutics...announced the closing of an oversubscribed $100 million Series C financing led by Newpath Partners, with participation from new investors Canaan Partners, Monograph Capital, and Insight Partners....Proceeds from the Series C will be used to commence two Phase 2 clinical trials for the company’s lead program, ABX-002...In the second half of 2024, Autobahn plans to initiate Phase 2 trials designed to provide biological and clinical proof-of-concept of ABX-002 as an adjunctive treatment for patients with major depressive disorder (MDD) and patients with bipolar disorder depression....With the proceeds from this raise, Autobahn will also advance ABX-101, a next-generation, brain-penetrant, oral sphingosine 1-phosphate (S1P) receptor modulator for the treatment of neuroimmunologic and neuroinflammatory disorders, into Phase 1 clinical testing."

Financing • New P2 trial • CNS Disorders • Depression • Major Depressive Disorder